Akcea Therapeutics (AKCA) PT Trimmed to $39 at BMO Capital; Pfizer Deal Provides 'Immediate Value'
Tweet Send to a Friend
BMO Capital analyst Do Kim lowered the price target on Akcea Therapeutics, Inc. (NASDAQ: AKCA) to $39.00 (from $43.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
